FDA warned US Chem Labs that it sells unapproved and misbranded Semaglutide, Tirzepatide, and Thymalin drugs online.
What happened
FDA reviewed www.uschemlabs.com in October 2023 and found the website offering Semaglutide, Tirzepatide, and Thymalin for sale in the United States. The site made claims that the products treat diabetes, support weight loss, or affect the immune and endocrine systems, even though labeling called them "research chemicals only" and "not for human consumption." FDA concluded the products are unapproved new drugs and misbranded, and said it was particularly concerned that Thymalin was marketed for use in children.
What FDA found
The products are unapproved new drugs sold without an FDA-approved application.
sections 505(a) and 301(d) of the FD&C Act, 21 U.S.C. 355(a) and 331(d)The product labeling lacks adequate directions for use, so the drugs are misbranded.
section 502(f)(1) of the FD&C Act, 21 U.S.C. 352(f)(1)Website claims show the products are intended as drugs for human use despite "research chemicals only" statements.
section 201(g)(1) of the FD&C Act, 21 U.S.C. 321(g)(1)Thymalin is marketed for use in children even though FDA has not evaluated it for safety, effectiveness, or quality.
What FDA wants
FDA asks US Chem Labs to notify it in writing within 15 working days of the steps taken to address the violations, including explanations and supporting documents. If corrective actions cannot be completed in that time, the company must state why and when it will finish.
Who should pay attention
- online sellers of research chemicals and peptides
- clinics or compounding pharmacies considering unapproved semaglutide or tirzepatide
- consumers buying weight-loss or immune products from websites
This is a summary. Read the original letter on fda.gov.